Moderna Available For Sale Securities Debt Securities Current increased by 2.9% to $3.30B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 24.2%, from $4.35B to $3.30B. Over 5 years (FY 2020 to FY 2025), Available For Sale Securities Debt Securities Current shows an upward trend with a 10.1% CAGR.
An increase suggests higher liquidity and a conservative cash management strategy, while a decrease may indicate cash deployment for operations or acquisitions.
This represents the portion of a company's investment portfolio consisting of debt securities that are expected to be so...
Common among large-cap pharmaceutical firms maintaining significant cash reserves for R&D and M&A activities.
current_assets_available_for_sale_securities_debt_securi_87ec82| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.39B | $3.36B | $3.88B | $5.07B | $5.02B | $5.32B | $6.70B | $5.48B | $4.66B | $4.64B | $5.70B | $6.47B | $6.01B | $5.22B | $5.10B | $4.35B | $3.85B | $3.37B | $3.20B | $3.30B |
| QoQ Change | — | +40.6% | +15.6% | +30.6% | -0.8% | +5.9% | +25.9% | -18.1% | -15.0% | -0.4% | +22.8% | +13.6% | -7.1% | -13.1% | -2.4% | -14.6% | -11.5% | -12.5% | -5.0% | +2.9% |
| YoY Change | — | — | — | — | +110.5% | +58.6% | +72.6% | +8.2% | -7.3% | -12.8% | -14.9% | +18.1% | +29.0% | +12.5% | -10.5% | -32.8% | -35.9% | -35.4% | -37.2% | -24.2% |